Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. Central Illustration
【저자키워드】 COVID-19, omega-3, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, statin, ARDS, acute respiratory distress syndrome, niacin, PCR, polymerase chain reaction, ICU, Intensive care unit, CRP, C-reactive protein, COVID-19, coronavirus disease-2019, EPA, eicosapentaenoic acid, ACE, angiotensin-converting enzyme, fibrate, DHA, Docosahexaenoic acid, RCT, Randomized controlled trial, HDL, high-density lipoprotein, lipid-modulating agent, CETP, cholesterol ester transfer protein, NAD, nicotinamide adenine dinucleotide, SOC, standard of care,